Communique from extraordinary general meeting of 2cureX AB (publ)
Today, April 2, 2019, an extraordinary general meeting was held in 2cureX AB (publ). A summary of the resolutions follows below. The resolutions were passed with the required majority.
Determination on the number of members of the board
The Meeting resolved that the Board of Directors shall consist of five (5) board members.
Election of a new board member
The Meeting resolved that Camilla Huse Bondesson shall be elected as a Board member. Furthermore, the meeting resolved to dismiss Juan Farré, Simon Hesse Hoffman and Ulrich Spengler, who at their own request requested a resignation from the Board. Other Board members remain.
Decision to authorize the Board to decide on issue
The Meeting resolved to authorise the Board of Directors, on one occasion, with pre-emption rights for the shareholders, for the period up to the next upcoming Annual General Meeting to resolve on new issue of shares.
The number of shares to be issued in accordance with the authorisation can equal a total amount not exceeding 25 000 000 SEK in issue payment.
The issue will be subject to a market-based subscription price, with reservation to a market-based issue discount when applicable, and payment, in addition to cash payment, can be done through offset, or otherwise with terms.
New share issue, decided in accordance with the authorisation, should be done with the purpose of bringing working capital to the business and/or capital for the development of the business.
The Board, or other by the Board appointed, is authorized to decide on minor corrections required for registration with the Swedish Companies Registration Office.
Malmö in April 2019
2cureX AB (publ)
Board of Directors
For more information about 2cureX:
|Ole Thastrup, Chief Executive Officer||Maarten van der Linden, Chief Business Officer|
|E-mail: email@example.com||E-mail: firstname.lastname@example.org|
|Telephone: +45 22 11 53 99||Telephone: +45 22 90 24 69|
Telephone: +46 40 615 14 15
2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented method for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumours that are functionally similar to the patient’s tumour. From a large panel of approved cancer treatments IndiTreat® selects the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.
IndiTreat® is currently being clinically validated in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical studies are conducted at major cancer hospitals in Denmark, Germany and United Kingdom.
The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).